Dental products company Envista Holdings (NYSE: NVST) announced better-than-expected revenue in Q2 CY2026, with sales up 7.1% year on year to $730.5 million. Its non-GAAP profit of $0.41 per share was 22.1% above analysts’ consensus estimates.

Is now the time to buy NVST? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Envista’s second quarter results were shaped by balanced growth across all major geographies and a continued focus on operational execution. Management pointed to resilient demand for dental care, especially in consumables and diagnostics, as a stabilizing influence despite macroeconomic uncertainty. CEO Paul Keel highlighted that new product launches in endodontics and orthodontics supported share gains, while margin expansion was driven by manufacturing productivity and cost control initiatives. The quarter also benefited from robust free cash flow conversion and ongoing progress in both reporting segments.

Looking ahead, Envista’s updated guidance is anchored by expectations of continued core growth and operational leverage, though management expects revenue growth to moderate due to fewer billing days in the fourth quarter. The company’s outlook incorporates the impact of China’s volume-based procurement (VBP) reforms in orthodontics and implants, which are expected to compress prices but potentially increase market share. CFO Eric Hammes stated, “Our guidance reflects both the timing of VBP in China and our confidence in maintaining price discipline outside of that market.” Envista will also continue to invest in new product development and commercial execution to support sustained profitability.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to broad-based product demand, geographic diversification, and margin improvements, while also highlighting the effects of regulatory shifts in China.

• New product launches: Significant contributions came from ZenSeal Pro, an endodontic sealer designed for improved clinical efficacy, and DemiPro, a cordless curing light aimed at enhancing ergonomic use in dental procedures. These innovations are expected to reinforce share gains in the consumables segment.

• Geographic diversification: Growth was consistent across North America, Europe, APAC, and Latin America. While North America showed some softness, strength in other regions, particularly post-pandemic recovery in diagnostics, provided balance.

• Market shifts in China: The ongoing implementation of volume-based procurement (VBP) reforms in China led to anticipated price compression in orthodontics and implants. Management expects that, despite price declines, Envista’s established market share may result in higher volumes and a stronger competitive position.

• Operational efficiency: The Envista Business System drove improvements in manufacturing productivity and general and administrative expense control, supporting both gross margin and adjusted EBITDA margin expansion. Initiatives in supply chain and targeted price actions helped offset rising input costs and tariff pressures.

• Implant business progress: Investment in new products and acquisitions, such as the Versah osseodensification technology, contributed to implant segment growth. Biomaterials and digital workflow offerings within the implant portfolio provided additional avenues for revenue diversification and margin accretion.

Drivers of Future Performance

Envista’s outlook is shaped by price and volume strategies, China policy shifts, and ongoing product investments.

• China VBP impact: Management anticipates that volume-based procurement will compress orthodontics and implant prices in China during the second half of the year. However, the company expects to offset this with increased market share and a rebound in volumes, especially as pent-up demand is released post-VBP.

• Billing day headwind: The reduction of four billing days in the fourth quarter will impact reported revenue growth, leading to a slowdown in the second half. Management clarified that, when normalized for this effect, underlying growth should remain consistent with the first half’s pace.

• Sustained investment: Envista plans to continue allocating resources to R&D and commercial initiatives. Increased spending in these areas, particularly for product launches and salesforce expansion, is expected to support mid-term growth but may limit further near-term EBITDA margin expansion.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will watch (1) the execution of China’s VBP reforms and their effect on Envista’s market share and volume recovery, (2) progress of recently launched products in driving consumables and implant share gains, and (3) the stabilization of margins amid continued investments in R&D and commercial initiatives. The upcoming Investor Day will also serve as a key signpost for strategy updates and long-term priorities.

Envista currently trades at $28.40, in line with $28.66 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.